Shanghai Pharmaceuticals Holding Co (2607) Stock Statistics & Valuation Metrics

Shanghai Pharmaceuticals Holding Co has a market cap or net worth of $56.87B. The enterprise value is HK$80.46B.

Shanghai Pharmaceuticals Holding Co has 919,072,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shanghai Pharmaceuticals Holding Co’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 4.49%.

The current PE Ratio of Shanghai Pharmaceuticals Holding Co is 10.31. Shanghai Pharmaceuticals Holding Co’s PEG ratio is -0.28.

In the last 12 months, Shanghai Pharmaceuticals Holding Co had revenue of 260.30B and earned 3.77B in profits. Earnings per share was 1.02.

In the last 12 months, operating cash flow was 3.44B and capital expenditures 0.00, giving a free cash flow of 7.71B billion.

Shanghai Pharmaceuticals Holding Co pays an annual dividend of HK$0.087, resulting in a dividend yield of 4.83%

Shanghai Pharmaceuticals Holding Co upcoming earnings date is Apr 25, 2025, TBA Not Confirmed.

Shanghai Pharmaceuticals Holding Co as a current ratio of 1.33, with Debt / Equity ratio of 67.90%

In the past 12 months, Shanghai Pharmaceuticals Holding Co has paid 1.89B in taxes.

Shanghai Pharmaceuticals Holding Co EV to EBITDA ratio is 4.70, with an EV/FCF ratio of 22.65.

Shanghai Pharmaceuticals Holding Co has $42.39B in cash and marketable securities with ¥31.66B in debt, giving a net cash position of $5.73B billion.

Gross margin is 11.18%, with operating margin of 2.95%, and net profit margin of 1.45%.

The average price target for Shanghai Pharmaceuticals Holding Co is $13.42, which is 11.43% higher than the current price. The consensus rating is Moderate Buy